about
Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale[Diagnosis of normal pressure hydrocephalus in elderly patients: a review].[Specificity of epileptic seizures in the elderly: A proposed electro-clinical scale].[Diabetes mellitus and cognition: is there a link?].[Neurological manifestations of type 1 Gaucher's disease: Is a revision of disease classification needed?]Distinctive features of microsaccades in Alzheimer's disease and in mild cognitive impairment.Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration.The stress response factor daf-16/FOXO is required for multiple compound families to prolong the function of neurons with Huntington's diseaseTime course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study.Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.Sleep disorders and their impacts on healthy, dependent, and frail older adults.Postoperative admission to a dedicated geriatric unit decreases mortality in elderly patients with hip fractureIsolated cardiac troponin rise does not modify the prognosis in elderly patients with hip fracture.A new multimodal geriatric discharge-planning intervention to prevent emergency visits and rehospitalizations of older adults: the optimization of medication in AGEd multicenter randomized controlled trial.Time perception in patients with dementia with Lewy bodies.GREFON recommendations for assessment of instrumental activities of daily living in memory clinics.Association Between Psychotropic and Cardiovascular Iatrogenic Alerts and Risk of Hospitalizations in Elderly People Treated for Dementia: A Self-Controlled Case Series Study Based on the Matching of 2 French Health Insurance Databases.Association between Cognitive Status before Surgery and Outcomes in Elderly Patients with Hip Fracture in a Dedicated Orthogeriatric Care Pathway.Perception of Alzheimer's disease in the French population.Prognostic Value of Serum Procalcitonin After Orthopedic Surgery in the Elderly Population.Prodromal stage of disease (dementia) with Lewy bodies, how to diagnose in practice?Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.Neuropsychiatric symptoms in elderly inpatients: a multicenter cross-sectional study.Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders.Scurvy in hospitalized elderly patients.Successful Cognitive Aging: Between Functional Decline and Failure of Compensatory Mechanisms.[Consensus statement on severe dementia].[Recent neuropathology of parkinsonian syndromes].The dysexecutive syndrome of Alzheimer's disease: the GREFEX study.Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial.Intact Procedural Knowledge in Patients with Alzheimer's Disease: Evidence from Golf Putting.Development of a short form of the Severe Impairment Battery.Sporadic Creutzfeldt-Jakob disease mimicking nonconvulsive status epilepticus.Pressure ulcers are associated with 6-month mortality in elderly patients with hip fracture managed in orthogeriatric care pathway.Exposure to psychotropics in the French older population living with dementia: a nationwide population-based study.Circulating microparticles and procoagulant activity in elderly patients.Biomarkers of vascular dysfunction and cognitive decline in patients with Alzheimer's disease: no evidence for association in elderly subjects.Post-Herpes zoster myelitis in a very old patient: A complication not to be missed.Utility of 123I-FP-CIT SPECT for dementia diagnoses and therapeutic strategies in elderly patients.[Use of nondeclarative and automatic memory processes in motor learning: how to mitigate the effects of aging].
P50
Q28741794-2E5FAE57-9999-4740-AF75-E2A64E2BB7D9Q30582248-8E56AE93-7DCA-46DA-AF9D-15E1653BA805Q33157020-1E4C5C32-848E-442A-B24E-E84F0E42B189Q33368986-80AA4AEB-B4CF-45F4-BF8E-FC13A99AD47DQ33373178-277E3E2F-C489-44F9-B745-514EC9FEDD0EQ33689048-7EBDAB1E-B9EB-4A5B-B8C2-B12C09B6B74FQ33753826-F95F4D3F-0993-499A-ACB2-BE9761BAEB32Q33822501-A15FFFBC-6393-4481-88B3-7B3B0EE5ACC7Q35454079-3A473868-DB04-4D13-920F-7AF7586CCEA8Q35579238-9B868E7C-E2BD-44D7-9B57-B29725AB6B0FQ37418991-D28D02FE-ED81-4C97-B658-0062E295B1ECQ37483563-4719EC03-9A9E-4AE0-BEA1-9DABFBCB5837Q37656393-346E3953-8299-4718-9BFD-873CBF0B35C5Q37957144-E8139200-656F-4C18-B36E-A3E19CE1A6BFQ38391582-D7E66B6A-CB36-4D10-8AA9-D01FFE6D2F0AQ38732850-93A328AC-90AF-425D-B1BC-6EF63B8101C0Q38885551-B62490CD-5404-4787-94FA-87AD9622094BQ39136361-050AB361-FD7D-404B-BCB4-6C527E468157Q39221232-56310749-70B1-423E-A5FE-E014E803E9F8Q39546735-5297F7FB-8468-4A6B-8AF1-9D037902D88EQ40168020-E2379291-F81A-4D0B-8016-2F6B52333472Q40448022-457DF608-C4C5-4E7D-8EAF-60FF188523DFQ40787331-225CE3BD-4C72-46CA-912E-26501D279755Q40902356-1881DCD7-F1BC-4D53-BF73-2ABB8C245718Q42975305-D667BD3E-0E52-4870-B00A-BA2442C021F4Q43136792-7171AFA7-5566-47BE-A51D-E325D324A445Q44243098-7D9949E7-8336-4906-B9CC-24D1E9FC1818Q44458070-65671856-A9EA-4B36-9213-9F4F2989FBE0Q45052966-1C61C4FA-7584-4CD1-AE0B-A8235E68CE16Q45796238-819F75DB-B3B8-4145-84FC-A10687FCAAD9Q46580002-1A735B5B-6341-44A3-B74C-10B8809E25F7Q47239605-9EEAF2A4-E612-4825-A06B-72B6D8D26F99Q48211442-AFDC7EC0-675D-47BA-925C-753E0CD28287Q48598570-F6760FF2-5D7A-4260-AF71-9B2A27D77972Q50206887-B14E81D0-2DD1-44DC-A1CB-107978B2D2FAQ50591830-FDFC1999-4264-4D6D-8F85-8FA4CB768DEDQ50675225-1C7B0B6B-6F26-4153-95B0-DE979950BDC5Q50786576-FE670592-F817-4BA0-A63C-3BFC42B4A4ECQ50865522-2BEA62CC-C89A-4D0D-A651-88C6DD357F9EQ50977476-99BE819C-B8D8-43D7-8C3A-87E7F5832D36
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marc Verny
@ast
Marc Verny
@en
Marc Verny
@es
Marc Verny
@nl
Marc Verny
@sl
type
label
Marc Verny
@ast
Marc Verny
@en
Marc Verny
@es
Marc Verny
@nl
Marc Verny
@sl
prefLabel
Marc Verny
@ast
Marc Verny
@en
Marc Verny
@es
Marc Verny
@nl
Marc Verny
@sl
P106
P21
P31
P3835
marc-verny
P496
0000-0001-7960-9705